IL6 and inflammatory bowel disease: This first-in-class decoy protein exclusively blocks IL-6 proinflammatory trans-signaling and has shown clinical efficacy in early phase IIa trials for ulcerative colitis/inflammatory bowel disease (IBD) without immunosuppression but with p-STAT3 reduction in the inflamed IBD mucosa [ClinicalTrials.gov #NCT03235752), (275).